Impact of Biosimilars in Psoriasis Treatment

被引：0
|
作者：
Torres, Tiago [1 ,2 ]
Filipe, Paulo [3 ,4 ,5 ]
Selores, Manuela [1 ,2 ]
机构：
[1] Ctr Hosp Porto, Serv Dermatol, Oporto, Portugal
[2] Univ Porto, Inst Ciencias Biomed Abel Salazar, P-4100 Oporto, Portugal
[3] Ctr Hosp Lisboa Norte, Serv Dermatol, Lisbon, Portugal
[4] Univ Lisbon, Fac Med, P-1699 Lisbon, Portugal
[5] Univ Lisbon, Inst Mol Med, Unidade Invest Dermatol, P-1699 Lisbon, Portugal
来源：
ACTA MEDICA PORTUGUESA | 2013年 / 26卷 / 06期
关键词：
Biological Agents; Biosimilar Pharmaceuticals; Psoriasis/drug therapy; Portugal;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：646 / 648
页数：3
相关论文
共 50 条
  • [21] Psoriasis Comorbidities and Their Treatment Impact
    Taliercio, Mark
    Lebwohl, Mark
    DERMATOLOGIC CLINICS, 2024, 42 (03) : 405 - 416
  • [22] Drug survival and safety of biosimilars and originator adalimumab in the treatment of psoriasis: a multinational cohort study
    Phan, Duc Binh
    Jourdain, Hugo
    Gonzalez-Quesada, Alicia
    Zureik, Mahmoud
    Rivera-Diaz, Raquel
    Sahuquillo-Torralba, Antonio
    Descalzo-Gallego, Miguel Angel
    Lunt, Mark
    Garcia-Doval, Ignacio
    Sbidian, Emilie
    Warren, R. B.
    Yiu, Zenas Z. N.
    BMJ OPEN, 2023, 13 (07):
  • [23] Portuguese Position Paper on the Use of Biosimilars in Psoriasis
    Torres, Tiago
    Ferreira, Ana
    Ferreira, Paulo
    Henriques, Martinha
    Leite, Luiz
    Magina, Sofia
    Marques Pinto, Gabriela
    Oliveira, Hugo
    Sousa Basto, Artur
    Bello, Rui Tavares
    Varela, Paulo
    Massa, Antonio
    Selores, Manuela
    Filipe, Paulo
    ACTA MEDICA PORTUGUESA, 2016, 29 (09): : 574 - 577
  • [24] Biosimilars in psoriasis: what should your positioning be?
    Ruiz-Villaverde, Ricardo
    Galan-Gutierrez, Manuel
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (01) : 81 - 86
  • [25] Biosimilars in psoriasis: What can we expect?
    Radtke, Marc Alexander
    Augustin, Matthias
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2014, 12 (04): : 306 - 312
  • [26] Reassurance Techniques Do Not Significantly Impact Confidence in Biosimilars for Psoriasis: A Survey of a Convenience Sample of Individuals with Self-Identified Psoriasis
    Matthew L. Hrin
    Jeremy K. Bray
    Steven R. Feldman
    Dermatology and Therapy, 2022, 12 : 2173 - 2180
  • [27] Biosimilars for psoriasis: clinical studies to determine similarity
    Blauvelt, A.
    Puig, L.
    Chimenti, S.
    Vender, R.
    Rajagopalan, M.
    Romiti, R.
    Skov, L.
    Zachariae, C.
    Young, H.
    Prens, E.
    Cohen, A.
    van der Walt, J.
    Wu, J. J.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (01) : 23 - 33
  • [28] Biosimilars for Psoriasis-Experience from Europe
    Cohen, Arnon D.
    Torres, Tiago
    Boehncke, Wolf-Henning
    de Rie, Menno
    Jullien, Denis
    Naldi, Luigi
    Ryan, Caitriona
    Strohal, Robert
    Skov, Lone
    van de Kerkhof, Peter
    van der Walt, Joelle M.
    Wu, Jashin J.
    Zachariae, Claus
    Puig, Lluis
    Young, Helen
    CURRENT DERMATOLOGY REPORTS, 2019, 8 (01) : 26 - 34
  • [29] Reassurance Techniques Do Not Significantly Impact Confidence in Biosimilars for Psoriasis: A Survey of a Convenience Sample of Individuals with Self-Identified Psoriasis
    Hrin, Matthew L.
    Bray, Jeremy K.
    Feldman, Steven R.
    DERMATOLOGY AND THERAPY, 2022, 12 (09) : 2173 - 2180
  • [30] An update on the impact of depression on the treatment of psoriasis
    Bell, Katheryn
    Balogh, Esther A.
    Feldman, Steven R.
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (06) : 695 - 703
12345